Barriers to Biosimilar Approval: Creating Clarity Through the Publication of Product-Class Specific Guidances [PDF]
, 2016 McEnrue, Martin
core
Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. [PDF]
World J GastroenterolKritzinger J +8 more
europepmc +1 more source
Characterization of a Long-Acting Anti-Human MASP-2 Antibody for the Treatment of Complement-Related Diseases. [PDF]
J Inflamm ResHan X +10 more
europepmc +1 more source
Will the emerging private-label market access channel help or hinder biosimilar market access? [PDF]
J Manag Care Spec PharmMehr SR.
europepmc +1 more source
Efficacy & safety of adalimumab biosimilar in axial spondyloarthritis: A retrospective study from a tertiary care centre in South India. [PDF]
Indian J Med ResGopalan A, Gavali M, Yerram K.
europepmc +1 more source
An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany. [PDF]
Front Public HealthRaitner I +6 more
europepmc +1 more source
Comparative outcomes of aflibercept biosimilars and reference aflibercept in nAMD: a systematic review and meta-analysis. [PDF]
BMJ Open OphthalmolSawires K, Nithianandan H, Somani S.
europepmc +1 more source
Efficacy and safety of sintilimab plus a bevacizumab biosimilar combined with transarterial chemoembolization for advanced hepatocellular carcinoma. [PDF]
Medicine (Baltimore)Yang J, Xu Q, Wu S.
europepmc +1 more source
How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013 [PDF]
, 2015 core +1 more source
CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial. [PDF]
BMJ OpenDai R +5 more
europepmc +1 more source